Canbisol (Nabidrox), is a synthetic cannabinoid derivative that is the dimethylheptyl homologue of 9-nor-9β-hydroxyhexahydrocannabinol (HHC). It is a potent agonist at both the CB1 and CB2receptors, with a binding affinity of 0.1 nM at CB1 and 0.2 nM at CB2.[1] It is mainly used in scientific research, in receptor binding studies to determine the structure and function of the cannabinoid receptors,[2][3][4] but has been made illegal in some countries due to its possible abuse potential as a cannabinomimetic drug.[5]
^Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, et al. (September 1997). "Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase". Journal of Medicinal Chemistry. 40 (20): 3228–33. doi:10.1021/jm970126f. PMID9379442.
^Rhee MH, Nevo I, Bayewitch ML, Zagoory O, Vogel Z (December 2000). "Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor". Journal of Neurochemistry. 75 (6): 2485–91. doi:10.1046/j.1471-4159.2000.0752485.x. PMID11080201. S2CID18339666.
^Zhang R, Hurst DP, Barnett-Norris J, Reggio PH, Song ZH (July 2005). "Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template". Molecular Pharmacology. 68 (1): 69–83. doi:10.1124/mol.104.007823. PMID15840841. S2CID6488891.
(what is this?) (verify)
